Fier de la présence persistante de l'uB dans le prestigieux classement de Shanghai malgré la compétitivité toujours + intense des universités anglo-saxonnes. Félicitations au Président THOMAS et aux équipes des labo. de recherche pour leur travail scientifique remarquable !

Analysis found patients receiving anti-VEGF inhibitors for diabetic macular edema at >2/3rd of their visits, a measure of treatment intensity, generally had better 1yr visual acuity and anatomic outcomes. @phgabriellemd @SydneySaveSight @FRB_Research https://t.co/RXGm5MnM8m

Excellent piece of work led by @phgabriellemd @CHUDijon! Glad to participate from @hospitalclinic @idibaps in another meaningful @AAOjournal paper from the global @FRB_Research team 🌍👁️💪 Keep up the hard work!!! @SydneySaveSight @Sydney_Uni #RealWorldData #IntravitrealTherapy

Real-world unmet needs in the management of poorly responsive neovascular age-related macular degeneration in Europe: data from the FRB! Registry https://t.co/MPOH2afwSI @phgabriellemd @CHUDijon @FRB_Research @SydneySaveSight @Sydney_Uni

SSR has upgraded its macular degeneration module to capture data for both wet and dry macular degeneration. We are discussing this exciting development with Users in an upcoming webinar. Visit our website for more details.

The article is available in #openaccess A huge thank you to my mentors Catherine Creuzot-Garcher and Mark Gillies and my co-authors Daniel Barthelmes, Hemal Mehta, @Vincedaien , and Vuong Nguyen. @CHUDijon @Univ_BFC @univbourgogne

Why read it? To stay updated with the comprehensive knowledge on #DME. RCT and Real-world evidence #RWE are combined to provide evidence-based guidelines to manage #DME.

The aim? To shed light on the complementary nature of "real-world" data #RWD compared to clinical trials in managing diabetic macular oedema #DME, drawing insights from the @FRB_Research registry.

Thrilled to share this article featured in @ElsevierConnect #ProgressinRetinalandEyeResearch, marking nearly 2 years of work since my fellowship at @SydneySaveSight @FRB_Research Registry @Sydney_Uni

🥳 Exciting news from the world of #ophthalmology! It's not every day that one gets to publish as the first author in the most prestigious journal in their field #research #retina 👁 🎉 🎊

From randomised controlled trials to real-world data: Clinical evidenc...

Our colleagues in France have led an analysis on the effect of HbA1c level and glomerular filtration rate on treatment outcomes in patients with #DME receiving anti-VEGF injections. The study used data from the Fight Retinal Blindness! registry. Read more below.👀

Study highlights hallucinated citations when using an AI chatbot to recommend ophthalmic sources and create scientific abstracts.

In this randomized trial of low-dose 0.01% atropine eyedrops vs placebo, 0.01% atropine eyedrops did not slow myopia progression or axial elongation over two years, which does not support its use in US children. Stronger concentrations should be studied.

https://t.co/7JIDCKC5Ux

In a randomized controlled trial, surgical vitrectomy was not superior to pneumatic displacement in managing submacular hemorrhage secondary to age-related #maculardegeneration, with TPA and ranibizumab added to each arm. @phgabriellemd @CHUDijon https://t.co/ObIgKQUuJl

STAR Trial: Surgery Not Superior to Pneumatic Displacement for Submacular Hemorrhage https://t.co/jb2SZgl4eH via @mdmagazine

#Ophthalmology #retina #AMD #research #Science 😃👁️🔬🤓

Feeling happy and proud :) not every day that you receive that kind of email from the blue journal @aao_ophth @AAOjournal Achievement of an enormous French collaborative work. More information on the findings of our RCT on the treatment of submacular hemorrhage soon @CHUDijon

In Memoriam - Professor Gabriel Coscas (1931 - 2023) We extend our heartfelt condolences to Florence Coscas, her family, and her ophthalmology family in Créteil. A giant has left us. On behalf of Euretina, thank you, Prof Gabriel Coscas🙏 https://t.co/MJ3lpOHg0j